Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baidu

Coinbase

Analysts are calling for significant gains in these fast-paced stocks.

5 Growth Stocks With 110% to 393% Upside, According to Wall Street

Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.

Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q2 2021 Results - Earnings Call Transcript

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) moved higher by 3.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 82.81% year over year to ($0.33), which beat the estimate of ($1.21).

Intercept Pharmaceuticals: Q2 Earnings Insights

Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter

Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Intercept Pharmaceuticals (NASDAQ:ICPT) unveils its next round of earnings this Thursday, July 29. Get prepared with Benzinga's ultimate preview for Intercept Pharmaceuticals's Q2 earnings.

Earnings Outlook For Intercept Pharmaceuticals

Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results prior to market open on Thursday, July 29, 2021. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021

NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the Raymond James 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 at 1:20 p.m. ET.

Intercept to Present at the Raymond James 2021 Human Health Innovation Conference

Blink Charging

Dave & Buster's

Reddit's retail investors may soon be swooning over this under-the-radar trio of heavily short-sold companies.

Are These the Next Meme Stocks?

NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer.

Intercept Appoints M. Michelle Berrey, M.D.

Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Intercept (ICPT) Moves 8% Higher: Will This Strength Last?

Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.

Intercept (ICPT) Ocaliva's Prescribing Information Updated

New contraindication applies to a subset of patients with primary biliary cholangitis (PBC) with decompensated cirrhosis, a prior decompensation event, or with compensated cirrhosis who have evidence of portal hypertension New contraindication applies to a subset of patients with primary biliary cholangitis (PBC) with decompensated cirrhosis, a prior decompensation event, or with compensated cirrhosis who have evidence of portal hypertension

Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information

The FDA has issued a statement restricting the use of Intercept Pharmaceuticals Inc's (NASDAQ: ICPT) Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis. PBC is a rare, chronic disease affecting the ducts in the liver that carry bile, which helps with digestion.

FDA Restricts Use Of Intercept's Ocaliva In Liver Disease with Advanced Cirrhosis Citing Risk Of Serious Liver Injury

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 4:50 p.m. ET.

Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference

Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations.

Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat

Intercept Pharmaceuticals' (ICPT) CEO Jerry Durso on Q1 2021 Results - Earnings Call Transcript

Intercept (ICPT) delivered earnings and revenue surprises of 20.26% and 1.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Tops Revenue Estimates

Worldwide Ocaliva® net sales of $81.7M, representing 12% growth over the prior year quarter

Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Inovio Pharmaceuticals

Sarepta Therapeutics

Analysts believe these underperformers could nearly double over the next 12 months.

3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street

The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results?

With Important Trial Results Due in June, Is This Drugmaker a Good Buy Now?

Nikola

Plug Power

Skillz

Vaxart

Analysts' consensus price targets imply that these stocks can more than double over the next 12 months.

News for Intercept Pharma Stock (ICPT)